Japan · Delayed Price · Currency is JPY Daiichi Sankyo Company Earnings Call Transcripts
Fiscal Year 2026
-
Revenue rose 12.1% year-on-year, led by ENHERTU and DATROWAY, with core operating profit up 8.8%. Oncology sales drove growth, while operating profit was impacted by one-time costs. No change to full-year guidance; focus remains on expanding key drug indications and managing generic competition.
-
Significant growth was achieved through a strategic shift to oncology, led by ENHERTU and DATROWAY, with robust financial performance and global expansion. The company is advancing its ADC platform, expanding indications, and investing in next-generation technologies for sustained growth.
-
Q2 FY2025 revenue rose 10.5% year-on-year, led by oncology, but core operating profit fell 4.8% due to higher costs and one-time items. Full-year revenue guidance was raised, with strong growth in Enhertu and Datroway, while American Regent faces generic competition. FX and legal risks persist.
-
Revenue grew 8.8% year-over-year, driven by strong oncology sales, especially ENHERTU and DATROWAY, with operating profit up 32.1%. The company raised its DATROWAY sales forecast and reaffirmed its DOE target, while monitoring U.S. tariffs and advancing R&D in oncology.
Fiscal Year 2025
-
The event highlighted robust growth in the oncology pipeline, with multiple new ADC approvals, strong market uptake, and a focus on expanding manufacturing and research platforms. Strategic initiatives aim for global leadership in oncology by 2030, supported by innovation in ADCs, immuno-oncology, and supply chain expansion.
-
Sustainability management is driven by investment in human capital, science, and patient-centricity, with a focus on global talent, innovation, and robust governance. The upcoming five-year plan and 2035 vision will integrate ESG, double materiality, and strategies for post-Enhertu growth.
-
Multiple phase III trials showed ENHERTU and Dato-DXd significantly improve outcomes in high-risk breast and ovarian cancers, with favorable safety and potential to set new standards of care. Accelerated approval strategies are underway, and DS-3939 is advancing in multiple tumor types, especially lung cancer.
-
I-DXd demonstrated robust efficacy and manageable safety in relapsed ES-SCLC, including patients with brain metastases and those previously treated with platinum or T-cell engagers. The program is advancing rapidly with breakthrough therapy designation and ongoing pivotal trials, aiming for broad applicability and differentiation through a favorable safety profile.
-
Significant clinical advances were reported for ENHERTU and Dato-DXd in breast, gastric, and lung cancers, with robust efficacy and manageable safety. Biomarker-driven strategies are being integrated to optimize patient selection and increase trial success, with several pivotal readouts expected in 2025.
-
Revenue and profit surged in FY2024, led by strong global sales of Enhertu and milestone payments from strategic partnerships. FY2025 targets include JPY 2 trillion in revenue, higher dividends, and continued investment in oncology and ADCs, with risks from FX and potential U.S. tariffs.
-
The business is entering a catalyst-rich period, with major growth expected from new Enhertu and Datroway indications, expanded patient eligibility, and strong U.S. and European performance. Strategic alliances, rapid reimbursement, and increased testing are driving market penetration and future revenue growth.
-
Q3 FY2024 saw strong revenue and profit growth, led by ENHERTU's global expansion and new approvals. FY2024 and FY2025 guidance remains robust despite DATROWAY delays, with mainstay products expected to offset shortfalls.
-
Revenue and operating profit are set for double-digit growth, driven by global expansion and strong ADC sales. The pipeline is advancing with new approvals, pivotal trials, and digital pathology innovation, while shareholder returns and manufacturing capacity are being enhanced.
-
Q2 FY2024 saw revenue rise 21.5% and core operating profit jump 74.8% year-on-year, driven by strong global sales of oncology products, especially Enhertu. FY2024 guidance was raised across all key metrics, with continued investment in R&D and strategic alliances.
Fiscal Year 2024
-
Sustainability efforts focus on global growth, innovation, and human capital, with ongoing challenges in emissions reduction and gender diversity. Leadership development, board diversity, and transparent compensation are prioritized, while strategic partnerships and new research hubs drive R&D. The company is enhancing talent pipelines and preparing for its next midterm business plan.
-
Key updates include robust clinical progress for DXd ADCs in breast and lung cancer, expansion of manufacturing capacity to meet rising global demand, and advanced biomarker strategies to optimize patient selection. Regulatory milestones are on track, with pivotal trial readouts and new formulations expected in 2025.
-
DESTINY-Breast06 demonstrated significant PFS benefit for Enhertu in HER2-low and ultra-low metastatic breast cancer, with consistent efficacy and manageable safety. Updated and new data across breast and lung cancer support ongoing expansion of the DXd ADC platform and may drive regulatory approvals and broader patient access.